You just read:

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

News provided by

Merck KGaA

Feb 16, 2019, 17:14 ET